Login Register Cart 0
Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Implication of Covid-19 on Neurological Complications with Specific Emphasis on Alzheimer’s and Parkinson’s Disease

Author(s): Ankita Sood, Ravi Goyal, Harshdeep Singh, Tapan Behl, Sandeep Arora, Balraj Saini and Rajwinder Kaur*

Volume 21, Issue 3, 2022

Published on: 20 August, 2021

Page: [235 - 245] Pages: 11

DOI: 10.2174/1871527320666210820092817

Price: $65

conference banner
Abstract

It is noticeable how the novel coronavirus has spread from the Wuhan region of China to the whole world, devastating the lives of people worldwide. All the data related to the precautionary measures, diagnosis, treatment, and even the epidemiological data are being made freely accessible and reachable in a very little time as well as being rapidly published to save humankind from this pandemic. There might be neurological complications of COVID-19 and patients suffering from neurodegenerative conditions like Alzheimer’s disease and Parkinson’s disease might have repercussions as a result of the pandemic. In this review article, we have discussed the effect of SARS-CoV-2 viral infection on the people affected with neurodegenerative disorders such as Parkinson’s and Alzheimer’s. It primarily emphasizes two issues, i.e., vulnerability to infection and modifications of course of the disease concerning the clinical neurological manifestations, the advancement of the disease and novel approaches to support health care professionals in disease management, the susceptibility to these diseases, and impact on the severity of disease and management.

Keywords: COVID-19, CNS, Alzheimer’s disease, Parkinson’s disease, neurological complications, pneumonia

« Previous Next »
Graphical Abstract

[1]
Ouassou H, Kharchoufa L, Bouhrim M, et al. The pathogenesis of coronavirus disease 2019 (COVID-19): Evaluation and prevention. J Immunol Res 2020; 2020: 1357983.
[http://dx.doi.org/10.1155/2020/1357983] [PMID: 32671115]
[2]
Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr 2020; 87(4): 281-6.
[http://dx.doi.org/10.1007/s12098-020-03263-6] [PMID: 32166607]
[3]
Hussain A, Kaler J, Tabrez E, Tabrez S, Tabrez SSM. Novel COVID-19: A comprehensive review of transmission, manifestation, and pathogenesis. Cureus 2020; 12(5): e8184.
[http://dx.doi.org/10.7759/cureus.8184] [PMID: 32566425]
[4]
Bulut C, Kato Y. Epidemiology of COVID-19. Turk J Med Sci 2020; 50(SI-1): 563-70.
[http://dx.doi.org/10.3906/sag-2004-172] [PMID: 32299206]
[5]
Chatterjee P, Nagi N, Agarwal A, et al. The 2019 novel coronavirus disease (COVID-19) pandemic: A review of the current evidence. Indian J Med Res 2020; 151(2 & 3): 147-59.
[http://dx.doi.org/10.4103/ijmr.IJMR_519_20] [PMID: 32362642]
[6]
Beghi E, Feigin V, Caso V, Santalucia P, Logroscino G. COVID-19 infection and neurological complications: Present findings and future predictions. Neuroepidemiology 2020; 54(5): 364-9.
[http://dx.doi.org/10.1159/000508991] [PMID: 32610334]
[7]
Serrano-Castro PJ, Estivill-Torrús G, Cabezudo-García P. Impact of SARS-CoV-2 infection on neurodegenerative and neuropsychiatric diseases: A delayed pandemic? Neurología (Engl Ed) 2020; 35(4): 245-51.
[8]
Available from:https://www.medicalnewstoday.com/articles/coronavirus-early-symptoms#early-symptoms accessed on 10 Feb 2021.
[9]
Pereira A. Long-term neurological threats of COVID-19: a call to update the thinking about the outcomes of the coronavirus pandemic. Front Neurol 2020; 11: 308.
[http://dx.doi.org/10.3389/fneur.2020.00308] [PMID: 32362868]
[10]
Harapan H, Itoh N, Yufika A, et al. Coronavirus disease 2019 (COVID-19): A literature review. J Infect Public Health 2020; 13(5): 667-73.
[http://dx.doi.org/10.1016/j.jiph.2020.03.019] [PMID: 32340833]
[11]
Bhidayasiri R, Virameteekul S, Kim JM, Pal PK, Chung SJ. COVID-19: An early review of its global impact and considerations for Parkinson’s disease patient care. J Mov Disord 2020; 13(2): 105-14.
[http://dx.doi.org/10.14802/jmd.20042] [PMID: 32344993]
[12]
Dhama K, Khan S, Tiwari R, et al. Coronavirus disease 2019- COVID-19. Clin Microbiol Rev 2020; 33(4): 33.
[http://dx.doi.org/10.1128/CMR.00028-20] [PMID: 32580969]
[13]
Papa SM, Brundin P, Fung VSC, et al. Impact of the COVID-19 pandemic on Parkinson’s disease and movement disorders. Mov Disord 2020; 35(5): 711-5.
[http://dx.doi.org/10.1002/mds.28067] [PMID: 32250460]
[14]
Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol 2020; 92(4): 418-23.
[http://dx.doi.org/10.1002/jmv.25681] [PMID: 31967327]
[15]
Fotuhi M, Mian A, Meysami S, Raji CA. Neurobiology of COVID-19. J Alzheimers Dis 2020; 76(6): 3-19.
[16]
Sulzer D, Antonini A, Leta V, et al. COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside. NPJ Parkinsons Dis 2020; 6(1): 18.
[http://dx.doi.org/10.1038/s41531-020-00123-0] [PMID: 32885037]
[17]
Li J, Long X, Huang H, Tang J, Zhu C, Hu S. Resilience of Alzheimer’s disease to COVID-19. J Alzheimers Dis 2020; 1-7.
[18]
Available from:https://www.alz.org/help-support/caregiving/coronavirus-(covid-19)-tips-for-dementia-care accessed on 10 Feb 2021.
[19]
Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020; 579(7798): 265-9.
[http://dx.doi.org/10.1038/s41586-020-2008-3] [PMID: 32015508]
[20]
World Health Organization. Coronavirus disease 2019 (COVID-19). Situation Report 2020; pp 51.
[http://dx.doi.org/10.15585/mmwr.mm6913e2]
[21]
Gorbalenya AE, Baker SC, Baric RS. Severe acute respiratory syndrome-related coronavirus: the species and its viruses-a statement of the Coronavirus Study Group. bioRxiv 2020.
[22]
Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579(7798): 270-3.
[http://dx.doi.org/10.1038/s41586-020-2012-7] [PMID: 32015507]
[23]
Available from:https://www.worldometers.info/coronavirus accessed on 10 Feb 2021.
[24]
WHO Coronavirus disease (COVID-19). Available from:https://covid19.who.int/(accessed 10 February 2021) accessed 10 February 2021.
[25]
Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov 2016; 15(5): 327-47.
[http://dx.doi.org/10.1038/nrd.2015.37] [PMID: 26868298]
[26]
Tong ZD, Tang A, Li KF, et al. Potential presymptomatic transmission of SARS-CoV-2, Zhejiang Province, China, 2020. Emerg Infect Dis 2020; 26(5): 1052-4.
[http://dx.doi.org/10.3201/eid2605.200198] [PMID: 32091386]
[27]
Rocklov J, Sjodin H, Wilder-Smith A. COVID-19 outbreak on the Diamond Princess cruise ship: estimating the epidemic potential and effectiveness of public health countermeasures. J Travel Med 2020; 27(3): taaa030.
[28]
Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: A retrospective review of medical records. Lancet 2020; 395(10226): 809-15.
[http://dx.doi.org/10.1016/S0140-6736(20)30360-3] [PMID: 32151335]
[29]
Trippella G, Ciarcià M, Ferrari M. COVID-19 in pregnant women and neonates: A systematic review of the literature with quality assessment of the studies. Pathogens 2020; 9(6): 485.
[30]
Di Toro, F, Gjoka, M, Di Lorenzo, G. et al. Impact of COVID-19 on maternal and neonatal outcomes: A systematic review and meta-analysis. Clin Microb Infect 2020; 27(1): 36-46.
[31]
Available from: https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/faqs-management-of-infants-born-to-covid-19-mothers/
[32]
Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med 2020; 382: 2268-70.
[http://dx.doi.org/10.1056/NEJMc2008597]
[33]
Moriguchi T, Harii N, Goto J. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis 2020; 94: 55-8.
[34]
Beyrouti R, Adams ME, Benjamin L, et al. Characteristics of ischaemic stroke associated with COVID-19. J Neurol Neurosurg Psychiatry 2020; 91(8): 889-91.
[http://dx.doi.org/10.1136/jnnp-2020-323586] [PMID: 32354768]
[35]
Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: Imaging features. Radiol Soci North Am 2020; 201187.
[36]
Toscano G, Palmerini F, Ravaglia S, et al. Guillain-Barré syndrome associated with SARS-CoV-2. N Engl J Med 2020; 382(26): 2574-6.
[http://dx.doi.org/10.1056/NEJMc2009191] [PMID: 32302082]
[37]
Pal M, Berhanu G, Desalegn C, Kandi V. Severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2): An update. Cureus 2020; 12(3): e7423.
[http://dx.doi.org/10.7759/cureus.7423] [PMID: 32337143]
[38]
Ge H, Wang X, Yuan X, et al. The epidemiology and clinical information about COVID-19. Eur J Clin Microbiol Infect Dis 2020; 39(6): 1011-9.
[http://dx.doi.org/10.1007/s10096-020-03874-z] [PMID: 32291542]
[39]
Jan H, Faisal S, Khan A. COVID-19: Review of epidemiology and potential treatments against 2019 novel coronavirus. Discov 2020; 8(2)
[40]
US FDA, News / events , COVID-19 update Available from:https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment accessed 28 August 2020.
[41]
Available from:https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments Accessed on 3 January 2020.
[42]
Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020; 77(6): 683-90.
[http://dx.doi.org/10.1001/jamaneurol.2020.1127] [PMID: 32275288]
[43]
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708-20.
[http://dx.doi.org/10.1056/NEJMoa2002032] [PMID: 32109013]
[44]
Matías-Guiu J, Gomez-Pinedo U, Montero-Escribano P, Gomez-Iglesias P, Porta-Etessam J, Matias-Guiu JA. Should we expect neurological symptoms in the SARS-CoV-2 epidemic? Neurologia (Engl Ed) 2020; 35(3): 170-5.
[http://dx.doi.org/10.1016/j.nrleng.2020.03.002] [PMID: 32299636]
[45]
Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol 2020; 92(6): 552-5.
[http://dx.doi.org/10.1002/jmv.25728] [PMID: 32104915]
[46]
Li K, Wohlford-Lenane C, Perlman S, et al. Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4. J Infect Dis 2016; 213(5): 712-22.
[http://dx.doi.org/10.1093/infdis/jiv499] [PMID: 26486634]
[47]
Doobay MF, Talman LS, Obr TD, Tian X, Davisson RL, Lazartigues E. Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol 2007; 292(1): R373-81.
[http://dx.doi.org/10.1152/ajpregu.00292.2006] [PMID: 16946085]
[48]
Fox NC, Petersen RC. The G8 dementia research summit-a starter for eight? Lancet 2013; 382(9909): 1968-9.
[http://dx.doi.org/10.1016/S0140-6736(13)62426-5] [PMID: 24332306]
[49]
Bostanciklioğlu M, Temiz E. Severe acute respiratory syndrome coronavirus 2 is penetrating to dementia research. Curr Neurovasc Res 2020; 17(4): 342-3.
[http://dx.doi.org/10.2174/1567202617666200522220509] [PMID: 32442082]
[50]
AboTaleb HA. Neurological complications in COVID-19 patients and its implications for associated mortality. Curr Neurovasc Res 2020; 17(4): 522-30.
[http://dx.doi.org/10.2174/1567202617666200727124704] [PMID: 32718292]
[51]
Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 2020; 323(18): 1775-6.
[http://dx.doi.org/10.1001/jama.2020.4683] [PMID: 32203977]
[52]
Covino M, De Matteis G, Santoro M, et al. Clinical characteristics and prognostic factors in COVID-19 patients aged ≥80 years. Geriatr Gerontol Int 2020; 20(7): 704-8.
[http://dx.doi.org/10.1111/ggi.13960] [PMID: 32516861]
[53]
Bianchetti A, Rozzini R, Guerini F, et al. Clinical presentation of COVID19 in dementia patients. J Nutr Health Aging 2020; 24(6): 560-2.
[http://dx.doi.org/10.1007/s12603-020-1389-1] [PMID: 32510106]
[54]
Gebre AK, Altaye BM, Atey TM, Tuem KB, Berhe DF. Targeting renin–angiotensin system against Alzheimer’s disease. Front Pharmacol 2018; 9: 440.
[http://dx.doi.org/10.3389/fphar.2018.00440] [PMID: 29760662]
[55]
SjödahlHammarlund C, Westergren A, Åström I, Edberg AK, Hagell P. The impact of living with Parkinson’s disease: balancing within a web of needs and demands. Parkinsons Dis 2018; 2018: 459-8651.
[56]
Antonini A, Leta V, Teo J, Chaudhuri KR. Outcome of Parkinson’s Disease patients affected by COVID-19. Mov Disord 2020; 35(6): 905-8.
[http://dx.doi.org/10.1002/mds.28104] [PMID: 32347572]
[57]
Wright JW, Harding JW. Importance of the brain Angiotensin system in Parkinson’s disease. Parkinsons Dis 2012; 2012: 860923.
[http://dx.doi.org/10.1155/2012/860923] [PMID: 23213621]
[58]
Mertens B, Vanderheyden P, Michotte Y, Sarre S. The role of the central renin-angiotensin system in Parkinson’s disease. J Renin Angiotensin Aldosterone Syst 2010; 11(1): 49-56.
[http://dx.doi.org/10.1177/1470320309347789] [PMID: 19861346]
[59]
Kuba K, Imai Y, Penninger JM. Angiotensin-converting enzyme 2 in lung diseases. Curr Opin Pharmacol 2006; 6(3): 271-6.
[http://dx.doi.org/10.1016/j.coph.2006.03.001] [PMID: 16581295]
[60]
Li J, Long X, Zhang Q, Fang X, Fang F, Lv X. Emerging evidence for neuropsycho-consequences of COVID-19. Curr Neuropharmacol 2021; 19(1): 92-6.
[http://dx.doi.org/10.2174/1570159X18666200507085335] [PMID: 32379592]
[61]
Santantonio TA, Messina G. Update on Coronavirus Disease 2019 (COVID-19). Open Neurol J 2020; 14(1): 4.
[http://dx.doi.org/10.2174/1874205X02014010004]
[62]
Rogers NT, Steptoe A, Cadar D. Frailty is an independent predictor of incident dementia: Evidence from the English Longitudinal Study of Ageing. Sci Rep 2017; 7(1): 15746.
[http://dx.doi.org/10.1038/s41598-017-16104-y] [PMID: 29146957]
[63]
Nikolich-Zugich J, Knox KS, Rios CT, Natt B, Bhattacharya D, Fain MJ. SARSCoV-2 and COVID-19 in older adults: What we may expect regarding pathogenesis, immune responses, and outcomes. Geroscience 2020; 42(2): 505-14.
[64]
Azarpazhooh MR, Avan A, Cipriano LE, Munoz DG, Sposato LA, Hachinski V. Concomitant vascular and neurodegenerative pathologies double the risk of dementia. Alzheimers Dement 2018; 14(2): 148-56.
[http://dx.doi.org/10.1016/j.jalz.2017.07.755] [PMID: 28974416]
[65]
Ghosh S, Durgvanshi S, Agarwal S, Raghunath M, Sinha JK. Current status of drug targets and emerging therapeutic strategies in the management of Alzheimer’s disease. Curr Neuropharmacol 2020; 18(9): 883-903.
[http://dx.doi.org/10.2174/1570159X18666200429011823] [PMID: 32348223]
[66]
Lien HNH, Koh EJ, Yap PLK. Understanding the obstacles to uptake of intervention programmes and services for persons with dementia. Curr Alzheimer Res 2020; 17(6): 526-33.
[http://dx.doi.org/10.2174/1567205017666200807192634] [PMID: 32851947]
[67]
Fernández-Martínez M, Castro J, Molano A, Zarranz JJ, Rodrigo RM, Ortega R. Prevalence of neuropsychiatric symptoms in Alzheimer’s disease and vascular dementia. Curr Alzheimer Res 2008; 5(1): 61-9.
[http://dx.doi.org/10.2174/156720508783884585] [PMID: 18288933]
[68]
Extremera BG. Recent advances in alzheimer research, Alzheimer’s disease: pathological and clinical findings. UAE: Bentham Science Publishers Ltd. 2019; 149-62.
[69]
de Erausquin GA, Snyder H, Carrillo M, Hosseini AA, Brugha TS, Seshadri S. The chronic neuropsychiatric sequelae of COVID-19: The need for a prospective study of viral impact on brain functioning. Alzheimers Dement 2021; 17(6): 1056-65.
[http://dx.doi.org/10.1002/alz.12255] [PMID: 33399270]
[70]
McMichael TM, Currie DW, Clark S, et al. Epidemiology of Covid-19 in a long-term care facility in King County, Washington. N Engl J Med 2020; 382(21): 2005-11.
[http://dx.doi.org/10.1056/NEJMoa2005412] [PMID: 32220208]
[71]
Singh RK. Recent trends in management of Alzheimer’s disease: Current therapeutic options and drug repurposing approaches. Curr Neuropharmacol 2020; 18(9): 868-82.
[http://dx.doi.org/10.2174/1570159X18666200128121920] [PMID: 31989900]
[72]
Falsey AR, Walsh EE. Respiratory syncytial virus infection in elderly adults. Drugs Aging 2005; 22(7): 577-87.
[http://dx.doi.org/10.2165/00002512-200522070-00004] [PMID: 16038573]
[73]
Bouza C, Martínez-Alés G, López-Cuadrado T. The impact of dementia on hospital outcomes for elderly patients with sepsis: A population-based study. PLoS One 2019; 14(2): e0212196.
[http://dx.doi.org/10.1371/journal.pone.0212196] [PMID: 30779777]
[74]
Brooks SK, Webster RK, Smith LE, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet 2020; 395(10227): 912-20.
[http://dx.doi.org/10.1016/S0140-6736(20)30460-8] [PMID: 32112714]
[75]
Lima CKT, Carvalho PMM, Lima IAAS. The emotional impact of Coronavirus 2019- nCoV (new Coronavirus disease). Psychiatry Res 2020; 287: 112915.
[76]
Brown EE, Kumar S, Rajji TK, Pollock BG, Mulsant BH. Anticipating and mitigating the impact of the COVID-19 pandemic on Alzheimer’s disease and related dementias. Am J Geriatr Psychiatry 2020; 28(7): 712-21.
[http://dx.doi.org/10.1016/j.jagp.2020.04.010] [PMID: 32331845]
[77]
Lanctôt KL, Amatniek J, Ancoli-Israel S, et al. Neuropsychiatric signs and symptoms of Alzheimer’s disease: New treatment paradigms. Alzheimers Dement (N Y) 2017; 3(3): 440-9.
[http://dx.doi.org/10.1016/j.trci.2017.07.001] [PMID: 29067350]
[78]
Lyketsos CG, Sheppard J-ME, Steinberg M, et al. Neuropsychiatric disturbance in Alzheimer’s disease clusters into three groups: the Cache County study. Int J Geriatr Psychiatry 2001; 16(11): 1043-53.
[http://dx.doi.org/10.1002/gps.448] [PMID: 11746650]
[79]
Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19. Lancet Neurol 2020; 19(9): 767-83.
[http://dx.doi.org/10.1016/S1474-4422(20)30221-0] [PMID: 32622375]
[80]
Nepal G, Rehrig JH, Shrestha GS, et al. Neurological manifestations of COVID-19: A systematic review. Crit Care 2020; 24(1): 421.
[http://dx.doi.org/10.1186/s13054-020-03121-z] [PMID: 32660520]
[81]
Montalvan V, Lee J, Bueso T, De Toledo J, Rivas K. Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review. Clin Neurol Neurosurg 2020; 194: 105921.
[http://dx.doi.org/10.1016/j.clineuro.2020.105921] [PMID: 32422545]
[82]
Ghannam M, Alshaer Q, Al-Chalabi M, Zakarna L, Robertson J, Manousakis G. Neurological involvement of coronavirus disease 2019: A systematic review. J Neurol 2020; 267(11): 3135-53.
[http://dx.doi.org/10.1007/s00415-020-09990-2] [PMID: 32561990]
[83]
Simard M, Hudon C, van Reekum R. Psychological distress and risk for dementia. Curr Psychiatry Rep 2009; 11(1): 41-7.
[http://dx.doi.org/10.1007/s11920-009-0007-z] [PMID: 19187707]
[84]
Boutoleau-Bretonnière C, Pouclet-Courtemanche H, Gillet A, et al. The effects of confinement on neuropsychiatric symptoms in Alzheimer’s disease during the COVID-19 crisis. J Alzheimers Dis 2020; 76(1): 41-7.
[http://dx.doi.org/10.3233/JAD-200604] [PMID: 32568211]
[85]
Lara B, Carnes A, Dakterzada F, Benitez I, Piñol-Ripoll G. Neuropsychiatric symptoms and quality of life in Spanish patients with Alzheimer’s disease during the COVID-19 lockdown. Eur J Neurol 2020; 27(9): 1744-7.
[http://dx.doi.org/10.1111/ene.14339] [PMID: 32449791]
[86]
Isaia G, Marinello R, Tibaldi V, Tamone C, Bo M. Atypical presentation of covid-19 in an older adult with severe Alzheimer disease. Am J Geriatr Psychiatry 2020; 28(7): 790-1.
[http://dx.doi.org/10.1016/j.jagp.2020.04.018] [PMID: 32381283]
[87]
Costanza A, Amerio A, Aguglia A, Escelsior A, Serafini G, Berardelli I. When sick brain and hopelessness meet: some matters on suicidality in the neurological patient. CNS Neurol Disord Drug Target 2020; 19(4): 257-63.
[88]
Wang H, Li T, Barbarino P, et al. Dementia care during COVID-19. Lancet 2020; 395(10231): 1190-1.
[http://dx.doi.org/10.1016/S0140-6736(20)30755-8] [PMID: 32240625]
[89]
Varala R, Bollikolla H. nCovid-19 in 2020: From Despair to Hope. Coronaviruses 2020; 1(1): 9-12.
[http://dx.doi.org/10.2174/2666796701999200621202839]
[90]
Pezzini A, Padovani A. Lifting the mask on neurological manifestations of COVID-19. Nat Rev Neurol 2020; 16(11): 636-44.
[http://dx.doi.org/10.1038/s41582-020-0398-3] [PMID: 32839585]
[91]
Ahmad I, Rathore FA. Neurological manifestations and complications of COVID-19: A literature review. J Clin Neurosci 2020; 77: 8-12.
[http://dx.doi.org/10.1016/j.jocn.2020.05.017] [PMID: 32409215]
[92]
Wenting A, Gruters A, van Os Y, et al. COVID-19 neurological manifestations and underlying mechanisms: A scoping review. Front Psychiatry 2020; 11: 860.
[http://dx.doi.org/10.3389/fpsyt.2020.00860] [PMID: 32973590]
[93]
Ahmed MU, Hanif M, Ali MJ, et al. Neurological manifestations of COVID-19 (SARS-CoV-2): A review. Front Neurol 2020; 11: 518.
[http://dx.doi.org/10.3389/fneur.2020.00518] [PMID: 32574248]
[94]
Sharifian-Dorche M, Huot P, Osherov M, et al. Neurological complications of coronavirus infection; a comparative review and lessons learned during the COVID-19 pandemic. J Neurol Sci 2020; 417: 117085.
[http://dx.doi.org/10.1016/j.jns.2020.117085] [PMID: 32871412]
[95]
Carod-Artal FJ. Neurological complications of coronavirus and COVID-19. Rev Neurol 2020; 70(9): 311-22.
[PMID: 32329044]
[96]
Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: A review. JAMA Neurol 2020; 77(8): 1018-27.
[http://dx.doi.org/10.1001/jamaneurol.2020.2065] [PMID: 32469387]
[97]
Aghagoli G, Marin BG, Katchur NJ, Chaves-Sell F, Asaad WF, Murphy SA. Neurological involvement in COVID-19 and potential mechanisms: A review. J Neurocrit Care 2020; 1-10.
[98]
Filatov A, Sharma P, Hindi F, Espinosa PS. Neurological complications of coronavirus disease (COVID-19): encephalopathy. Cureus 2020; 12(3): e7352.
[http://dx.doi.org/10.7759/cureus.7352] [PMID: 32328364]
[99]
Helmich RC, Bloem BR. The impact of the COVID-19 pandemic on Parkinson’s disease: hidden sorrows and emerging opportunities. J Parkinsons Dis 2020; 10(2): 351-4.
[http://dx.doi.org/10.3233/JPD-202038] [PMID: 32250324]
[100]
Matias-Guiu JA, Pytel V, Matías-Guiu J. Death rate due to COVID-19 in Alzheimer’s disease and frontotemporal dementia. J Alzheimers Dis 2020; 78(2): 537-41.
[http://dx.doi.org/10.3233/JAD-200940] [PMID: 33074240]
[101]
Canevelli M, Palmieri L, Raparelli V, et al. Prevalence and clinical correlates of dementia among COVID-19-related deaths in Italy. Alzheimers Dement (Amst) 2020; 12(1): e12114.
[http://dx.doi.org/10.1002/dad2.12114] [PMID: 33225041]
[102]
Available from: https://www.apdaparkinson.org/article/questions-about-pd-and-covid-19/
[103]
Simonetti A, Pais C, Jones M, et al. Neuropsychiatric symptoms in elderly with dementia during COVID-19 pandemic: definition, treatment, and future directions. Front Psychiatry 2020; 11: 579842.
[http://dx.doi.org/10.3389/fpsyt.2020.579842] [PMID: 33132939]
[104]
Fasano A, Elia AE, Dallocchio C, et al. Predictors of COVID-19 outcome in Parkinson’s disease. Parkinsonism Relat Disord 2020; 78: 134-7.
[http://dx.doi.org/10.1016/j.parkreldis.2020.08.012] [PMID: 32827969]
[105]
Zhang Q, Schultz JL, Aldridge GM, Simmering JE, Narayanan NS. Coronavirus Disease 2019 case fatality and Parkinson’s disease. Mov Disord 2020; 35(11): 1914-1915.
[http://dx.doi.org/10.1002/mds.28325]
[106]
Caso V, Federico A. No lockdown for neurological diseases during COVID19 pandemic infection. Neurol Sci 2020; 41(5): 999-1001.
[http://dx.doi.org/10.1007/s10072-020-04389-3] [PMID: 32270358]
[107]
Hatcher-Martin JM, Adams JL, Anderson ER, et al. Telemedicine in neurology: telemedicine work Group of the American Academy of neurology update. Neurology 2020; 94(1): 30-8.
[http://dx.doi.org/10.1212/WNL.0000000000008708] [PMID: 31801829]
[108]
Kim H, Jhoo JH, Jang JW. The effect of telemedicine on cognitive decline in patients with dementia. J Telemed Telecare 2017; 23(1): 149-54.
[http://dx.doi.org/10.1177/1357633X15615049] [PMID: 26541171]
[109]
Lancaster C, Koychev I, Blane J, Chinner A, Wolters L, Hinds C. Evaluating the feasibility of frequent cognitive assessment using the Mezurio smartphone app: observational and interview study in adults with elevated dementia risk. JMIR Mhealth Uhealth 2020; 8(4): e16142.
[http://dx.doi.org/10.2196/16142] [PMID: 32238339]
[110]
Brouillette RM, Foil H, Fontenot S, et al. Feasibility, reliability, and validity of a smartphone based application for the assessment of cognitive function in the elderly. PLoS One 2013; 8(6): e65925.
[http://dx.doi.org/10.1371/journal.pone.0065925] [PMID: 23776570]
[111]
Tieges Z, Stíobhairt A, Scott K, et al. Development of a smartphone application for the objective detection of attentional deficits in delirium. Int Psychogeriatr 2015; 27(8): 1251-62.
[http://dx.doi.org/10.1017/S1041610215000186] [PMID: 25742756]
[112]
Bossen A, Kim H, Steinhoff A, Strieker M, Williams K. Emerging roles for telemedicine and smart technologies in dementia care. Smart Homecare Technol Telehealth 2015; 3: 49.
[113]
Godwin KM, Mills WL, Anderson JA, Kunik ME. Technology-driven interventions for caregivers of persons with dementia: A systematic review. Am J Alzheimers Dis Other Demen 2013; 28(3): 216-22.
[http://dx.doi.org/10.1177/1533317513481091] [PMID: 23528881]
[114]
Finkel S, Czaja SJ, Schulz R, Martinovich Z, Harris C, Pezzuto D. E-care: A telecommunications technology intervention for family caregivers of dementia patients. Am J Geriatr Psychiatry 2007; 15(5): 443-8.
[http://dx.doi.org/10.1097/JGP.0b013e3180437d87] [PMID: 17463195]
[115]
Bloem BR, Dorsey ER, Okun MS. The coronavirus disease 2019 crisis as catalyst for telemedicine for chronic neurological disorders. JAMA Neurol 2020; 77(8): 927-8.
[http://dx.doi.org/10.1001/jamaneurol.2020.1452] [PMID: 32329796]
[116]
Armstrong N, Nugent C, Moore G, Finlay D. Using smartphones to address the needs of persons with Alzheimer’s disease. Ann Telecommun -. Ann Telecommun 2010; 65(9-10): 485-95.
[http://dx.doi.org/10.1007/s12243-010-0165-3]

Rights & Permissions Print Cite
Article Metrics
30
1
© 2024 Bentham Science Publishers | Privacy Policy